Halazepam

Halazepam is a benzodiazepine derivative that was marketed under the brand names Paxipam in the United States,[1] Alapryl in Spain,[2] and Pacinone in Portugal.[3]

Halazepam

Clinical data
Other names	9-chloro-6-phenyl-2-(2,2,2-trifluoroethyl)-2,5-diazabicyclo[5.4.0]undeca-5,8,10,12-tetraen-3-one
AHFS/Drugs.com	Micromedex Detailed Consumer Information
MedlinePlus	a684001
Pregnancy category	?
Routes of administration	Oral
ATC code	N05BA13 (WHO)
Legal status
Legal status	CA: Schedule IV DE: Prescription only (Anlage III for higher doses) US: Schedule IV
Pharmacokinetic data
Metabolism	Hepatic
Elimination half-life	14 hours (halazepam), 50–100 hours (metabolites).
Excretion	Renal
Identifiers
IUPAC name 7-chloro-5-phenyl-1-(2,2,2-trifluoroethyl)-3H-1,4-benzodiazepin-2-one
CAS Number	23092-17-3^Y
PubChem CID	31640
IUPHAR/BPS	7195
DrugBank	DB00801^Y
ChemSpider	29343^Y
UNII	320YC168LF
KEGG	D00338^Y
ChEMBL	ChEMBL970^Y
CompTox Dashboard (EPA)	DTXSID5023118
ECHA InfoCard	100.041.281
Chemical and physical data
Formula	C17H12ClF3N2O
Molar mass	352.74 g·mol^−1
3D model (JSmol)	Interactive image
SMILES FC(F)(CN1C(CN=C(C2=CC=CC=C2)C3=C1C=CC(Cl)=C3)=O)F
InChI InChI=1S/C17H12ClF3N2O/c18-12-6-7-14-13(8-12)16(11-4-2-1-3-5-11)22-9-15(24)23(14)10-17(19,20)21/h1-8H,9-10H2^Y Key:WYCLKVQLVUQKNZ-UHFFFAOYSA-N^Y
(verify)

Medical uses

Halazepam was used for the treatment of anxiety.[1]

Adverse effects

Adverse effects include drowsiness, confusion, dizziness, and sedation. Gastrointestinal side effects have also been reported including dry mouth and nausea.[1]

Pharmacokinetics and pharmacodynamics

Pharmacokinetics and pharmacodynamics were listed in Current Psychotherapeutic Drugs published in June 15, 1998 as follows:[4]

Onset of action	Intermediate to slow
Plasma half life	14 hr for parent drug and 30-100 hr for its metabolite
Peak plasma levels	1-3 hr for parent drug and 3-6 hf for its metabolite
Metabolism	Metabolized into desmethyldiazepam and 3-hydroxyhalazepam (in the liver)
Excretion	Excreted through kidneys
Protein binding	98% bound to plasma protein

Regulatory Information

Halazepam is classified as a schedule 4 controlled substance with a corresponding code 2762 by the Drug Enforcement Administration (DEA).[5]

Commercial production

Halazepam was invented by Schlesinger Walter in the U.S. It was marketed as an anti-anxiety agent in 1981. However, Halazepam is not commercially available in the United States because it was withdrawn by its manufacturer for poor sales.[1]

See also

• Benzodiazepines
• Nordazepam
• Diazepam
• Chlordiazepoxide
• Quazepam, fletazepam, triflubazam — benzodiazepines with trifluoromethyl group attached

References

1. "halazepam". Drugs.com. Retrieved December 11, 2014.
2. "Alapryl". Drugs.com. Retrieved December 11, 2014.
3. "Pacinone". Drugs.com. Retrieved December 11, 2014.
4. Quitkin, Frederick M. ... (1998). Current therapeutic drugs (2nd ed.). Washington: American Psychiatric Press. p. 166. ISBN 0880489944.
5. "SCHEDULES OF CONTROLLED SUBSTANCES". Code of Federal Regulations. 2012-04-01. pp. § 1308.14 Schedule IV. Retrieved December 12, 2014.

External links

• Inchem - Halazepam